About
About Jiangxi Synergy Pharmaceutical Co., Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic parkinsonism, hypolipidemic agents, migraine therapy, prostate cancer, endometriosis, anemia, atopic dermatitis, nervous system, digestive system, antipyretic analgesics and non-steroidal anti-inflammatory, anticoagulant, hypoglycemic drug, and antidepressant indications. It also provides intermediate products, including rivaroxaban, apixaban, empagliflozin, canagliflozin, ipragliflozin, mirabegron, vibegron, agomelatine, febuxostat, vildagliptin, vonoprazan fumarate, dabigatran etexilate mesylate, azilsartan base and medoxomil potassium, candesartan cilexetil, rimegepant, resmetirom, and opicapone. In addition, the company offers contract manufacturing organization (CMO) services, including production capacity, good manufacturing practice (GMP), regulatory support, research and development for process optimization and scale-up production, and environmental, health, and safety (EHS) management systems. It exports its products to Europe, the United States, Japan, and South Korea. Jiangxi Synergy Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Yichun, the People's Republic of China.
Research context
Jiangxi Synergy Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Jiangxi Synergy Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 10.5% below its 200 day moving average.
From a valuation standpoint, the stock is 14.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
Jiangxi Synergy Pharmaceutical Co., Ltd's total revenue sank by 27.1% to $96M since the same quarter in the previous year.
Its net income has increased by 48.6% to $10M since the same quarter in the previous year.
Finally, its free cash flow fell by 48.3% to $-78M since the same quarter in the previous year.
Based on the above factors, Jiangxi Synergy Pharmaceutical Co., Ltd gets an overall score of 2/5.